![]() |
|
|
Vol. 286, Issue 1, 328-333, July 1998
Department of Physiology, University of Texas Health Science Center, San Antonio, Texas
| |
Abstract |
|---|
|
|
|---|
Ovarian hormone deficiency decreases and estrogen (E2) and growth hormone (GH) administrations increase intestinal absorption of calcium (Ca++). However, the underlying mechanisms are uncertain. To examine whether alterations in the binding characteristics of intestinal estrogen receptors (ERs) are involved, we developed and validated methods for simultaneous measurement of intestinal ERs in cytosolic and nuclear fractions and applied these techniques to four groups of female rats: sham-operated, ovariectomized (Ovx), Ovx + 5 µg E2/kg b.wt./day and Ovx + 8 mg GH/kg. b.wt./day. All animals were killed on day 21, and mucosal cells harvested from the duodenum for ER determination. The cytosolic and nuclear ERs were 117.2 ± 2.7 fmol/mg protein and 64.9 ± 1.2 fmol/mg DNA, respectively, in sham-operated rats and decreased by 16.1% and 17.0% to 98.4 ± 1.7 fmol/mg protein and 53.8 ± 1.3 fmol/mg DNA, respectively in Ovx rats (P < .001). E2 therapy prevented completely the decrease in cytosolic and nuclear ERs that occurred in Ovx rat (126.1 ± 2.9 fmol/mg protein and 68.0 ± 3.0 fmol/mg DNA, respectively, in the E2-treated group). Similarly, GH administration prevented the decrease in cytosolic and nuclear ERs that resulted from ovariectomy (119.2 ± 3.2 fmol/mg protein and 63.4 ± 1.3 fmol/mg DNA, respectively, in the GH-treated group). The Kd of nuclear ER-ligand complex was 2.0 ± 0.03 nM in sham-operated rats and was slightly modulated by Ovx, E2 and GH (3.3 ± 0.02, 2.33 ± 0.09 and 2.23 ± 0.04 nM, respectively, P < .001), but the Kd of cytosolic ER-ligand complex was not altered by Ovx, E2 or GH. Our findings indicate that E2 deficiency down-regulates, whereas E2 and GH administrations up-regulate intestinal ERs and prevent ovariectomy-induced decrease in receptor binding affinity. We conclude that E2 deficiency, E2 and GH may modulate intestinal Ca++ absorption, in part, by altering the abundance and binding characteristics of intestinal ERs.
| |
Introduction |
|---|
|
|
|---|
Several
laboratories have demonstrated that intestinal
Ca++ absorption is low in
E2 deficiency and high in
E2 replete states (Gallagher et al.,
1979
, 1980
; Gallagher, 1990
; Heaney et al., 1978
; Francis
et al., 1984
; Morris et al., 1991
; Gennari
et al., 1990
). These findings suggest that
E2 is involved in the regulation of intestinal
absorption of Ca++. This view is supported by two
recent reports indicating that the epithelial cells of the small
intestine are direct targets of E2 action. In
1993, Thomas et al. demonstrated that IEC-6 intestinal crypt
cells and segments of the small intestine of rats contain ER mRNA and
that IEC-6 cells respond to E2 with increased
c-fos mRNA content. In the same year, Arjmandi et
al. (1993)
demonstrated that intestinal mucosal cells from all
segments of the small intestine contain ER immunoreactivity, express
the mRNA for ERs and respond directly to 17
-estradiol with enhanced
Ca++ transport that is suppressed by
transcription and protein synthesis inhibitors. In addition, they
reported that in rats E2 promoted intestinal
Ca++ absorption without altering plasma levels of
1,25(OH)2 D (Arjmandi et al., 1994
),
an acknowledged stimulator of intestinal Ca++
absorption. The conclusion from these studies is that intestinal mucosal cells contain functional ERs that respond directly to E2 to promote transcriptional activities and
Ca++ absorption. To extend the characterization
of the putative intestinal ER and investigate the factors involved in
its regulation we have developed techniques for examining intestinal
ERs by Scatchard analysis and determined the effects of ovariectomy,
E2 and GH administration on their abundance and
binding affinity. The hormonal regimens examined were chosen because
they are known to alter intestinal Ca++
absorption by mechanisms that are presently unclear. In this study, we
explored whether alterations in ER characteristics are components of
these mechanisms.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. [3H]E2 (90 Ci/mmol) were obtained from Amersham (Arlington Heights, IL). E2, DES, progesterone, testosterone, DNA, sodium azide, EDTA, DTT, NaSCN, HAP and phosphorus assay kit were purchased from Sigma Chemical (St. Louis, MO). Crystalline 1,25(OH)2D was a gift from Dr. M. Uskokovic of Hoffman La Roche, Inc. (Nutley, NJ). Serum 1,25 (OH)2D assay kit was obtained from Nichols Institute (San Juan Capistrano, CA). Recombinant human GH was provided by Genentech (South San Francisco, CA). The protein assay kit was from BioRad (Hercules, CA).
Animals and diets. Female Fischer 344 rats, aged 90 says, were purchased from Harlan Sprague-Dawley (Indianapolis, IN) and used for the experiment described below when they were 95 days old. On arrival at our institution, the rats were housed in a room maintained at 26°C on 14-hr light/10-hr dark cycles. During the experimental period, they were fed Harlan Teklad Laboratory diet (Madison, WI) that contained 0.93% Ca++, 0.65% phosphorus and 3.0 IU/g vitamin D and allowed free access to deionized drinking water.
The treatment of animals was in accordance with the guidelines of our Institutional Animal Care and Use Committee and the NIH Guide for the Care and Use of Laboratory Animals.Experimental protocol.
At 95 days of age, the rats were
divided into four weight-matched groups of 10 animals per group. Group
1 was sham-operated on. Groups 2, 3 and 4 were ovariectomized. Groups 1 and 2 received solvent vehicle daily. Groups 3 and 4 received 5 µg of
E2 and 8 mg GH/kg b.wt./day, respectively.
Hormones and solvent vehicle injections were given subcutaneously,
beginning from the day after surgery. Group 3 rats received
E2 administration daily for the first 12 days and
every other day thereafter. Solvent vehicle was administered to these
groups on alternate days after day 12. On day 21, all animals were
anesthetized with methoxyflurane and bled from the abdominal aorta. The
serum was separated and stored at
20°C for the analysis of
Ca++, phosphorus and
1,25(OH)2D concentrations. Duodenum was collected for receptor binding studies. The dose of E2 was
based on what we had found in other studies to be effective in
preventing ovariectomy-induced bone loss in rats (Kalu et
al., 1991
). The dose of GH is in the range that was found to be
effective in improving the mechanical strength of graft wounds
(Jørgensen et al., 1995
) and in increasing cancellous bone
volume in Ovx rats (Kalu et al., 1993
). Lower doses were
less efficacious (Kalu et al., 1991
, 1993
; Jørgensen et al., 1995
).
Tissue collection and preparation.
Twelve centimeters of
small intestine distal to the pylorus, designated the duodenum, was
excised, rapidly rinsed with ice-cold physiological saline and slit
lengthwise to expose the mucosa. The tissue was placed on a chilled
glass plate on an ice bath and mucosal cells scraped from the
underlying muscle with a glass slide. Nuclear and cytosolic fractions
from the duodenal mucosa cells were prepared essentially as described
by Bergman et al. (1987)
. Briefly, the cells were
homogenized in 3 volumes of ice-cold TED buffer (10 nM Tris·HCI, 1 mM
EDTA, 1 mM DTT and 0.2 g/liter sodium azide, pH 7.4). The homogenate
was placed on a 1.2 M sucrose pad (1:1) in 1.5 ml polypropylene
microtube and centrifuged at 6900 × g for 30 min. The
supernatant above the sucrose pad was removed and centrifuged at
105,000 × g for 1 hr at 4°C to yield the cytosolic
fraction. The sucrose pad was carefully removed, and the nuclear pellet
in the bottom was resuspended in a volume of TED buffer equal to the
volume of homogenate initially put on the sucrose pad.
Measurement of cytosolic and nuclear ERs.
Cytosolic and
nuclear ERs were measured by an adaptation of the technique of Bergman
et al. (1987)
. Aliquots (300 µl) of cytosolic and nuclear
fractions of duodenal mucosal cells were incubated with various
concentrations of [3H]E2
(0.5-8.0 nM) in the presence or absence of 1000-fold excess of
unlabeled E2 for 2 hr at 4°C. At the end of the
incubation, 100 µl of 2.5 M NaSCN, dissolved in TED buffer, was added
to the reaction mixture to a final concentration of 0.5 M NaSCN to
solubilize ER (Sica et al., 1980
), and the incubation was
continued for 20 hr (nuclear ER) or 40 hr (cytosolic ER). After the
incubation period, nuclear samples were centrifuged at 11,800 × g for 1 hr to pellet and remove chromatin (Bergman et
al., 1987
).
Specificity analysis of [3H]E2 binding to intestinal ER. Aliquots (300 µl) of cytosolic fractions prepared from duodenal mucosal cells were incubated for 16 hr with 1 nM [3H]E2 in the presence and absence of 500-, 1000- and 2000-fold excess of several unlabeled steroid hormones including DES, E2, 1,25(OH)2D, progesterone and testosterone. Bound and free [3H]E2 were separated by the HAP procedure. Percentage of specifically bound [3H]E2 was measured by scintillation counting.
Measurements of serum Ca++, phosphorus and 1,25(OH)2D. Serum samples were diluted with 0.1% lanthanum solution and analyzed for Ca++ by atomic absorption spectrophotometry (model 503; Perkin-Elmer, Norwalk, CT). Serum phosphorus was measured with a Sigma diagnostics phosphorus kit according to the manufacturer's technique. Serum 1,25(OH)2D was measured with a radioisotopic assay kit obtained from Nichols Institute, and the manufacturer's protocol was used in carrying out the assay.
General procedures and statistical analysis.
The protein
content of cytosolic fractions was determined by the method of Bradford
(1976)
. DNA content of nuclear preparations was measured by the method
of Schneider (1957)
using calf thymus DNA as standard. Comparison
between treatment groups involved estimation of means, standard errors
and analysis of variance (Snedecor and Cochran, 1967
). Analysis of
variance was performed using a StatView Statistical Package (Abacus
Concepts, Berkeley, CA) on a Macintosh IIsi computer. When the analysis
of variance indicated significant difference among mean values, the
differences were evaluated by using Fisher's protected
least-significant difference (Fisher's PLSD) multiple comparison
procedure (Fisher, 1935
). P
.05 was considered statistically
significant.
| |
Results |
|---|
|
|
|---|
Effects of ovariectomy, E2 and GH on body weights, uterine weights and serum parameters. Initial and final body weights were recorded and the uterus weighed at the termination of the study. The data are shown in table 1. Sham-operated, Ovx, Ovx + E2- and Ovx + GH-treated rats had similar mean body weights at the start of the study. Ovariectomy significantly increased body weight, and E2 therapy completely prevented the increase in body weight of Ovx rats. GH administration markedly increased body weights above those of Ovx rats. Ovariectomy caused atrophy of the uterus, as expected. E2 therapy not only completely prevented the uterine atrophy in Ovx rats but also increased the uterine weights above those sham-operated controls. In contrast, GH administration had no effect on uterine weight. Serum levels of Ca++, phosphorus and 1,25(OH)2D in sham-operated, Ovx, Ovx + E2- and Ovx + GH-treated rats were measured, and the data are given shown in table 1. Compared with sham-operated animals, the serum level of Ca++ was not significantly altered by ovariectomy but was increased by E2 and GH administrations. Ovariectomy caused a slight increase in serum phosphorus level, which was prevented by E2 and GH. Ovariectomy had no significant effect on serum 1,25(OH)2D levels, which were 63% and 34% lower in E2- and GH-treated rats, respectively, than in sham-operated rats.
|
Specificity analysis of [3H]E2 binding to intestinal ER. The specificity of [3H]E2 binding to intestinal ER was determined by competitive binding analysis using several potential steroid competitors of E2 binding to its receptor. That the binding of labeled E2 was specific for estrogenic compounds is demonstrated in figure 1. The figure indicates that only E2 and DES competed effectively with [3H]E2 for binding to duodenal cytosolic ER extracts, whereas progesterone, testosterone and 1,25(OH)2D did not, even at very high concentrations (2000-fold excess).
|
Characteristics of [3H]E2 binding to duodenal extracts. We established the characteristics of [3H]E2 binding to cytosolic and nuclear ERs by saturation and Scatchard analyses as described in the the text. [3H]E2-specific binding data for cytosolic and nuclear ER are shown in figures 2 and 3, respectively. The specific binding of [3H]E2 to duodenal extracts increased with increasing concentrations of [3H]E2 and exhibited a saturation profile for the nuclear fraction at 8 nM [3H]E2, but the saturation profile did not completely plateau at 8 nM [3H]E2 for the cytosolic fraction. Nonspecific binding was <50% of total binding of [3H]E2 at 8 nM for both fractions. Scatchard plots of the specific binding data revealed a single class of binding sites for both cytosolic and nuclear ERs with different Kd values for cytosolic and nuclear ERs as described in detail later.
|
|
Effects of ovariectomy, E2 and GH on the number of duodenal ERs. The number of ER binding sites (Bmax) was quantified by saturation and Scatchard analysis for the different rat groups and the data are summarized in figures 4 to 6. The means of the number of cytosolic and nuclear ERs were 117.2 ± 2.7 fmol/mg protein and 64.9 ± 1.2 fmol/mg DNA, respectively, in sham-operated rats and decreased significantly by 16.1% and 17.0% to 98.4 ± 1.7 fmol/mg protein and 53.8 ± 1.3 fmol/mg DNA, respectively, in Ovx rats (P < .001). In contrast, E2 therapy not only completely prevented the decrease in the number of cytosolic and nuclear ERs that occurred in Ovx rats, but E2 also increased the number of cytosolic ERs above those of sham-operated rats (cytosolic ER in Ovx + E2, 126.1 ± 2.0 fmol/mg protein; nuclear ER in Ovx + E2, 68.0 ± 3.0 fmol/mg DNA). Similarly, GH administration restored the decreased number of cytosolic and nuclear ERs that resulted from ovariectomy (from 98.4 ± 1.7 to 119.2 ± 3.2 fmol/mg protein in cytosolic fractions, and from 53.8 ± 1.3 to 63.4 ± 1.3 fmol/mg DNA for nuclear fractions).
|
|
|
Effects of ovariectomy, E2 and GH on the binding affinity to [3H]E2 to duodenal ER. The Kd values of ER-ligand complex for cytosolic and nuclear ERs for the different experimental groups were calculated from Scatchard plots of the binding studies and the data are summarized in figure 7. The Kd for nuclear ER-ligand complex was 2.04 ± 0.03 nM in sham-operated rats and increased significantly by 60% in Ovx rats to 3.26 ± 0.02 nM (P < .001). E2 and GH therapy prevented the increase in Kd that resulted from ovariectomy (2.33 ± 0.09 and 2.23 ± 0.04 nM for E2 and GH, respectively, P = N.S.). In contrast, the Kd of cytosolic ER-ligand complex observed in sham-operated rats was unaltered by ovariectomy, E2 or GH therapy and was higher than that observed for nuclear ERs in sham-operated rats.
|
| |
Discussion |
|---|
|
|
|---|
The effects of ovariectomy, E2 and GH on rat
intestinal ERs were investigated in this study. The changes in uterine
weights confirmed the success of ovariectomy and
E2 therapy. The markedly higher body weights in
GH-treated rats attest to the success of the GH treatment. The increase
in serum Ca++ we observed in
E2-treated rats is consistent with our previous reports (Kalu et al., 1991
), and similar results have been
observed by other investigators (Turner et al., 1987
; Thomas
et al., 1988
). However, our finding that GH increased serum
Ca++ in rats differs from other reports in which
GH had no effect on serum Ca++ level in humans
(Chipman et al., 1980
; Brixen et al., 1995
). Ovariectomy is known to alter phosphate homeostasis. A significant reduction in phosphorus levels has been reported in Ovx rats (Hietala, 1993
). In contrast, we observed an increase in phosphorus levels in
line with the reports of others that serum phosphate concentration increased after ovariectomy in both rats and humans (Morris et al., 1992
; Zofková et al., 1996
). Our finding
that E2 depressed ovariectomy-induced increase in
serum phosphorus level is consistent with previous report (Turner
et al., 1987
). GH has been reported to increase serum
phosphorus in humans (Chipman et al., 1980
) but not in pigs
(Denis et al., 1994
). Our data demonstrate that GH also
prevented ovariectomy-induced increase in serum phosphorus similar to
the effect of E2. Previous reports indicate that
the effects of hormones on serum 1,25(OH)2D
levels are complex (Deluca, 1974
; Spencer et al., 1981
). Our
finding that ovariectomy had no effect on serum
1,25(OH)2D level while E2
administration lowered its concentration is consistent with our
previous reports on rats (Kalu et al., 1991
). However, there
may be species differences as E2 has been
reported to increase serum 1,25(OH)2D levels in humans (Gallagher et al., 1980
; Van Hoff et al.,
1994
). It is of note that GH also decreased serum
1,25(OH)2D levels in this study. While a similar
decrease has been observed in humans (Chipman et al., 1980
),
GH has also been reported to increase serum
1,25(OH)2D levels in pigs (Denis et
al., 1994
) and intact rats (Fleet et al., 1994
) in
contrast to our findings in Ovx rats. The above observations underline
the complexity of the influence of hormones on serum
1,25(OH)2D levels.
Estrogen receptors are important elements not only in determining the
tissues that respond to E2 but also in predicting
the responsiveness of target tissues to the hormone. Because this is
the first report of in vivo modulation of intestinal ERs by humoral factors, the validity of our findings and conclusions depends,
in part, on the reliability of our measurement of the binding
characteristics of intestinal ERs. The assay we used is an adaptation
of the technique used for saturation and Scatchard analysis of
intestinal 1,25(OH)2D receptors (Wecksler and
Norman, 1979
; Horst et al., 1990
). Our findings indicate
that duodenal mucosal cells contain ERs with a single class of binding
sites for both cytosolic and nuclear ERs. The saturation analysis data of ER binding showed that the specific binding of
[3H]E2 became saturable
at 8 nM [3H]E2 for the
nuclear fraction, but the saturation profile did not plateau completely
at 8 nM [3H]E2 for the
cytosolic fraction. Although in preliminary experiments, we increased
the concentrations of
[3H]E2 for the cytosolic
ER binding above 8 nM, yet the saturation of specific binding in the
cytosdic fraction did not occur while nonspecific binding increased to
unacceptable levels (data not shown). We are unable to explain why the
specific binding of
[3H]E2 for the cytosolic
fraction did not become saturable. The binding sites for estrogen
interact in a specific fashion with estrogenic compounds such as DES
and E2 but have negligible cross-reactivity with
other steroids such as testosterone, progesterone and
1,25(OH)2D. In this study, cold DES and
E2 com-peted effectively and in a dose-dependent
manner with 3H-labeled E2,
and at 1000-fold excess concentration permitted only 34% and 13%
binding of [3H]E2 to
intestinal ERs, respectively. At the same fold excess concentration,
testosterone, progesterone and 1,25(OH)2D did not compete significantly with
[3H]E2 binding, attesting
to the specificity of our ER binding assay.
ERs are widely distributed in mammalian tissues, including the uterus,
breast, spleen, blood lymphocytes, kidney, brain, liver (Korach, 1979
;
Stancel et al., 1973
; Osborne et al., 1980
;
Athreya et al., 1989
; Lehrer et al., 1994
; Stock
et al., 1992
; Insel, 1990
; Freyschuss et al.,
1991
) and bone (Komm et al., 1988
; Ericksen et
al., 1988
). The presence of functional ERs in intestinal
epithelial cells was reported by Thomas et al. (1993)
.
Arjmandi et al. (1993)
demonstrated that rat intestinal cell
contain ER mRNAs. Later studies from our laboratory further
characterized the putative intestinal ERs using RT-PCR analysis,
Western blot analysis, Southern blot analysis, ligand binding assay and
gel shift assay. It was concluded from these studies that the duodenum
contains a variant ER gene that encodes a variant ER protein, and the
duodenal ER appears to be a functional variant ER protein of the
classic ER (Salih et al., 1996
). Our findings from the
current study clearly demonstrate that ovariectomy,
E2 and GH modulate the abundance and binding
characteristics of intestinal ERs. The decrease in cytosolic and
nuclear ERs due to ovarian hormone deficiency and its prevention by
E2 therapy were unequivocal. In addition, the number of cytosolic ERs rose with E2 therapy to
levels above those of sham-operated controls, suggestive but not proof
that E2 may have a stimulatory action on duodenal
ER synthesis as well. The effects of E2 therapy
on Kd are equally of note. While the
experimental paradigms did not alter the
Kd value for cytosolic ER, ovariectomy increased nuclear Kd by >40% while
E2 therapy prevented the increase in nuclear
extracts. These findings suggest that E2
regulates not only the number of its intestinal receptors, but the
binding affinity of the nuclear receptor to E2.
While the effect on binding affinity was unexpected, there is a
precedence for homologous regulation of ER by E2.
In mammals E2 has been shown to increase the
number of uterine ERs, presumably through the stimulation of receptor
synthesis at the level of transcription (Bergman et al.,
1992
).
The other significant observation in this study is the effect of GH on
ERs. GH has long been known to stimulate Ca++
absorption, but the action of the hormone is often linked to altered
levels of 1,25(OH)2D in humans (Chipman et
al., 1980
) and pigs (Denis et al., 1994
). Our current
findings that it prevents ovariectomy-induced decrease in intestinal ER
complements our recent finding that GH also prevents
ovariectomy-induced decrease in intestinal vitamin D receptors (Chen
et al., 1997
). Our findings indicate that GH has
"receptortropic" effects that are not due simply to a generalized
anabolic effect of GH on the gastrointestinal tract because receptor
numbers were expressed per milligram of cytosolic protein or nuclear
DNA. Recent reports indicate that GH can, indeed, induce ER synthesis
in primary cultures of hepatocytes by stimulating the transcription of
ER mRNA (Jørgensen et al., 1995
).
The changes in E2 binding characteristics we
observed in ovarian hormone deficiency and
E2-treated animals may have important pathophysiological implications. Despite the almost uniform agreement that hypoestrogenic states such as postmenopausal osteoporosis are
associated with intestinal Ca++ malabsorption
that is corrected by E2 therapy (Gallagher
et al., 1979
, 1980
; Gallagher, 1990
; Heaney et
al., 1978
; Francis et al., 1984
; Morris et
al., 1991
; Gennari et al., 1990
), the underlying mechanisms have remained uncertain. Recent observations indicate that
Ca++ malabsorption in hypoestrogenic states is
related, at least in part, to the abrogation of the direct and
stimulatory effects of E2 on intestinal
Ca++ absorption. This view is supported by the
finding that E2 can stimulate
Ca++ absorption in vivo without
altering 1,25(OH)2D levels (Arjmandi et
al., 1994
), and it enhances Ca++ uptake,
in vitro, by intestinal mucosal cells (Arjmandi et
al., 1993
). Our current findings suggest that alterations in the
abundance of intestinal ERs may be additional components of the
Ca++ malabsorption that occurs in hypoestrogenic
states and that is corrected by E2 therapy. It is
of note that nuclear receptor affinity was also decreased by
ovariectomy and corrected by E2 therapy, which
would reinforce the effects of estrogenic state on ER numbers and
consequently on intestinal Ca++ absorption. Other
findings suggest that there is also cross-talk between
E2 and vitamin D endocrine systems at the level
of the intestine, such that E2 deficiency
decreases and E2 repletion increases intestinal
vitamin D receptors (Chen et al., 1997
). In view of the
stimulatory effects of E2 and vitamin D on
intestinal Ca++ absorption, the lowering of their
intestinal receptors might contribute to the intestinal resistance to
the action of 1,25(OH)2D on
Ca++ absorption in hypoestrogenic states (Francis
et al., 1984
; Morris et al., 1991
; Gennari
et al., 1990
) and its correction by E2
therapy (Gennari et al., 1990
). However, a direct link
between ER regulation and Ca++ absorption remains
to be established.
| |
Acknowledgments |
|---|
We thank Dr. S. Yu for his help, Deanna Hedderich for typing the manuscript and Genentech, Inc., for their generous supply of recombinant human GH.
| |
Footnotes |
|---|
Accepted for publication March 31, 1998.
Received for publication June 12, 1997.
1 This study was supported in part by grants from the NIH AG 13309 and a University Grant Program for Osteoporosis Therapies from Procter and Gamble Pharmaceuticals.
Send reprint requests to: Dike N. Kalu Ph.D Department of Physiology University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive San Antonio TX 78284-7756. E-mail: KALU{at}uthscsa.edu
| |
Abbreviations |
|---|
E2, estrogen, or 17
-estradiol;
GH, growth hormone;
ER, estrogen receptor;
Ovx, ovariectomized;
[3H]E2, 17
-[2,4,6,
7-3H]estradiol;
DES, diethylstilbestrol;
HAP, hydroxyapatite;
1, 25(OH)2D, 1,25-dihydroxyvitamin D.
| |
References |
|---|
|
|
|---|
-estradiol on intestinal calcium absorption in rats.
Bone Miner
26:
181-189[Medline].
, 25-dihydroxyvitamin D and intestinal calcium absorption.
J Clin Endocrinol Metab
51:
321-324
-estradiol.
Bone Miner
14:
175-187[Medline].
-estradiol on cortical bone histomorphometry in growing rats.
J Bone Miner Res
2:
115-122[Medline].
25-dihydroxyvitamin D3-receptor complexes.
Anal Biochem
92:
314-323[Medline].This article has been cited by other articles:
![]() |
Y. Zhao, B. R. Martin, and C. M. Weaver Calcium Bioavailability of Calcium Carbonate Fortified Soymilk Is Equivalent to Cow's Milk in Young Women J. Nutr., October 1, 2005; 135(10): 2379 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cifuentes, J. P. Advis, and S. A. Shapses Estrogen Prevents the Reduction in Fractional Calcium Absorption Due to Energy Restriction in Mature Rats J. Nutr., August 1, 2004; 134(8): 1929 - 1934. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||